Immunotherapy before stomach cancer surgery to boost tumor immune cells
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This Phase 3 trial tests an “immunotherapy first” approach before surgery for certain stomach (gastric) cancers. The goal is to increase immune cells inside the tumor, which may improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old
- Your stomach cancer has been confirmed on biopsy/pathology and is a specific type (like signet ring, poorly differentiated, etc.)
- Scans before surgery (CT/MRI/PET-CT or look during surgery) show stage T2 or higher or lymph nodes involved
- You haven’t had other cancer treatments yet, including surgery, chemotherapy, radiation, targeted therapy, or immunotherapy
- You’re well enough for surgery (performance status 0 or 2) and expected to live more than 3 months
- Your heart, lungs, liver, and kidneys are stable enough, and you meet required blood test and infection-free limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests how well immunotherapy given before surgery (neoadjuvant treatment) works for locally advanced stomach cancer. It aims to improve outcomes by tailoring treatment to different “immunotypes” (how the immune system and tumor behave).
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether giving immunotherapy after surgery can help prevent stomach cancer from coming back. It is for patients whose tumors show certain markers that suggest immunotherapy may work well.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Hear when a new Advanced Gastric Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.